Display options
Cite
Dębniak T, Gromowski T, Scott RJ, et al. Management of ovarian and endometrial cancers in women belonging to HNPCC carrier families: review of the literature and results of cancer risk assessment in Polish HNPCC families. Hered Cancer Clin Pract. 2015;13(1):3doi: 10.1186/s13053-015-0025-2.
Dębniak, T., Gromowski, T., Scott, R. J., Gronwald, J., Huzarski, T., Byrski, T., Kurzawski, G., Dymerska, D., Górski, B., Paszkowska-Szczur, K., Cybulski, C., Serrano-Fernandez, P., & Lubiński, J. (2015). Management of ovarian and endometrial cancers in women belonging to HNPCC carrier families: review of the literature and results of cancer risk assessment in Polish HNPCC families. Hereditary cancer in clinical practice, 13(1), 3. https://doi.org/10.1186/s13053-015-0025-2
Dębniak, Tadeusz, et al. "Management of ovarian and endometrial cancers in women belonging to HNPCC carrier families: review of the literature and results of cancer risk assessment in Polish HNPCC families." Hereditary cancer in clinical practice vol. 13,1 (2015): 3. doi: https://doi.org/10.1186/s13053-015-0025-2
Dębniak T, Gromowski T, Scott RJ, Gronwald J, Huzarski T, Byrski T, Kurzawski G, Dymerska D, Górski B, Paszkowska-Szczur K, Cybulski C, Serrano-Fernandez P, Lubiński J. Management of ovarian and endometrial cancers in women belonging to HNPCC carrier families: review of the literature and results of cancer risk assessment in Polish HNPCC families. Hered Cancer Clin Pract. 2015 Jan 16;13(1):3. doi: 10.1186/s13053-015-0025-2. eCollection 2015. PMID: 25606063; PMCID: PMC4300044.
Copy Download .nbib Format: NLM
Share it on

Hered Cancer Clin Pract. 2015 Jan 16;13(1):3. doi: 10.1186/s13053-015-0025-2. eCollection 2015.

Management of ovarian and endometrial cancers in women belonging to HNPCC carrier families: review of the literature and results of cancer risk assessment in Polish HNPCC families.

Hereditary cancer in clinical practice

Tadeusz Dębniak, Tomasz Gromowski, Rodney J Scott, Jacek Gronwald, Tomasz Huzarski, Tomasz Byrski, Grzegorz Kurzawski, Dagmara Dymerska, Bohdan Górski, Katarzyna Paszkowska-Szczur, Cezary Cybulski, Pablo Serrano-Fernandez, Jan Lubiński

Affiliations

  1. Department o f Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, Szczecin, Poland.
  2. Discipline of Medical Genetics, Faculty of Health, University of Newcastle and Hunter Medical Research Institute, Newcastle, NSW Australia.

PMID: 25606063 PMCID: PMC4300044 DOI: 10.1186/s13053-015-0025-2

Abstract

BACKGROUND: Over half the cancer deaths in HNPCC families are due to extra-colonic malignancies that include endometrial and ovarian cancers. The benefits of surveillance for gynecological cancers are not yet proven and there is no consensus on the optimal surveillance recommendations for women with MMR mutations.

METHODS: We performed a systematic review of the literature and evaluated gynecological cancer risk in a series of 631 Polish HNPCC families classified into either Lynch Syndrome (LS, MMR mutations detected) or HNPCC (fulfillment of the Amsterdam or modified Amsterdam criteria).

RESULTS: Published data clearly indicates no benefit for ovarian cancer screening in contrast to risk reducing surgery. We confirmed a significantly increased risk of OC in Polish LS families (OR = 4,6, p < 0.001) and an especially high risk of OC was found for women under 50 years of age: OR = 32,6, p < 0.0001 (95% CI 12,96-81,87). The cumulative OC risk to 50 year of life was calculated to be 10%. Six out of 19 (32%) early-onset patients from LS families died from OC within 2 years of diagnosis. We confirmed a significantly increased risk of EC (OR = 26, 95% CI 11,36-58,8; p < 0,001). The cumulative risk for EC in Polish LS families was calculated to be 67%.

CONCLUSIONS: Due to the increased risk of OC and absence of any benefit from gynecological screening reported in the literature it is recommended that prophylactic oophorectomy for female carriers of MMR mutations after 35 year of age should be considered as a risk reducing option. Annual transvaginal ultrasound supported by CA125 or HE4 marker testing should be performed after prophylactic surgery in these women. Due to the high risk of EC it is reasonable to offer, after the age of 35 years, annual clinical gynecologic examinations with transvaginal ultrasound supported by routine aspiration sampling of the endometrium for women from either LS or HNPCC families. An alternative option, which could be taken into consideration for women preferring surgical prevention, is risk reducing total hysterectomy (with bilateral salpingo-oophorectomy) for carriers after childbearing is complete.

Keywords: Adnexectomy; Endometrial cancer; HNPCC; Lynch syndrome; Ovarian cancer

References

  1. Fam Cancer. 2013 Jun;12(2):295-300 - PubMed
  2. Med Oncol. 2014 Jan;31(1):808 - PubMed
  3. N Engl J Med. 2002 May 23;346(21):1609-15 - PubMed
  4. Am J Surg Pathol. 2014 Sep;38(9):1173-81 - PubMed
  5. Cancer. 2000 Oct 15;89(8):1765-72 - PubMed
  6. Cancer Control. 2009 Jan;16(1):14-22 - PubMed
  7. Fam Cancer. 2001;1(2):107-9 - PubMed
  8. J Clin Oncol. 2008 Dec 1;26(34):5530-6 - PubMed
  9. Cancer. 1995 Nov 15;76(10 Suppl):2011-5 - PubMed
  10. J Clin Oncol. 2008 Jan 1;26(1):20-5 - PubMed
  11. Int J Cancer. 2007 Feb 15;120(4):821-4 - PubMed
  12. Gastroenterology. 2005 Aug;129(2):415-21 - PubMed
  13. Obstet Gynecol. 2010 Feb;115(2 Pt 2):432-4 - PubMed
  14. Obstet Gynecol. 2007 Jul;110(1):18-25 - PubMed
  15. J Med Genet. 2005 Jun;42(6):491-6 - PubMed
  16. Cell. 1993 Dec 17;75(6):1215-25 - PubMed
  17. Gastroenterology. 2004 Jul;127(1):17-25 - PubMed
  18. J Clin Oncol. 2012 Dec 10;30(35):4409-15 - PubMed
  19. Gynecol Oncol. 2013 Nov;131(2):304-8 - PubMed
  20. N Engl J Med. 2006 Jan 19;354(3):261-9 - PubMed
  21. Int J Gynecol Cancer. 2008 Nov-Dec;18(6):1326-31 - PubMed
  22. Cancer. 2008 Jul 15;113(2):326-35 - PubMed
  23. Fam Cancer. 2011 Sep;10(3):535-43 - PubMed
  24. Cancer. 2002 Mar 15;94(6):1708-12 - PubMed
  25. Hered Cancer Clin Pract. 2013 Aug 12;11(1):9 - PubMed
  26. Fam Cancer. 2005;4(4):301-5 - PubMed
  27. Nature. 1994 Sep 1;371(6492):75-80 - PubMed
  28. Cell. 1993 Dec 3;75(5):1027-38 - PubMed
  29. Fam Cancer. 2012 Sep;11(3):467-71 - PubMed
  30. Arch Gynecol Obstet. 2012 Dec;286(6):1555-62 - PubMed
  31. Gynecol Oncol. 2001 Aug;82(2):223-8 - PubMed
  32. Fam Cancer. 2007;6(1):1-12 - PubMed
  33. Gynecol Oncol. 2014 Jun;133(3):526-30 - PubMed
  34. Patholog Res Int. 2012;2012:350309 - PubMed
  35. Fam Cancer. 2013 Mar;12(1):57-63 - PubMed
  36. Int J Gynecol Pathol. 2013 Mar;32(2):163-6 - PubMed
  37. Clin Transl Oncol. 2008 Jun;10(6):313-7 - PubMed
  38. N Engl J Med. 2003 Mar 6;348(10):919-32 - PubMed
  39. Fam Cancer. 2012 Sep;11(3):441-7 - PubMed
  40. J Med Genet. 2010 Feb;47(2):99-102 - PubMed
  41. Science. 1994 Mar 18;263(5153):1625-9 - PubMed
  42. Fam Cancer. 2013 Jun;12(2):273-7 - PubMed
  43. Int J Cancer. 2013 Dec 1;133(11):2596-608 - PubMed
  44. J Oncol Pract. 2011 Jan;7(1):43-7 - PubMed
  45. Gut. 2013 Jun;62(6):812-23 - PubMed
  46. N Engl J Med. 2002 May 23;346(21):1616-22 - PubMed
  47. Clin Genet. 2009 Feb;75(2):141-9 - PubMed
  48. JAMA. 2006 Sep 27;296(12):1507-17 - PubMed
  49. Gastroenterology. 2000 May;118(5):829-34 - PubMed
  50. Int J Cancer. 1995 Dec 20;64(6):430-3 - PubMed
  51. Tumour Biol. 2014 Jun;35(6):6127-38 - PubMed
  52. J Surg Oncol. 2013 Dec;108(7):433-7 - PubMed
  53. Acta Obstet Gynecol Scand. 2011 May;90(5):437-44 - PubMed
  54. J Clin Oncol. 2014 May 20;32(15):1547-53 - PubMed
  55. Clin Cancer Res. 2007 Jan 1;13(1):356-61 - PubMed
  56. Clin Genet. 2013 Apr;83(4):359-64 - PubMed
  57. Int J Cancer. 2008 Jul 15;123(2):444-9 - PubMed
  58. Gynecol Oncol. 2003 Oct;91(1):74-80 - PubMed
  59. Fam Cancer. 2009;8(4):391-7 - PubMed

Publication Types